Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors
Vasiliki Zoi, Vasiliki Galani, Chrissa Sioka, Georgios A Alexiou, Athanassios P Kyritsis, Gabriella D’Orazi · 2025
Read Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors by Vasiliki Zoi, Vasiliki Galani, Chrissa Sioka, Georgios A Alexiou, Athanassios P Kyritsis, Gabriella D’Orazi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12691215.txt.
Description
A peer-reviewed research article from Europe PMC (2025). Simple SummaryImmune checkpoint inhibitors have been largely investigated in several cancers with promising results. In glioblastoma (GBM), the efficacy of immunotherapy is limited primarily due to the tumor’s immunosuppressive environment and the presence of the blood–brain barrier.
Catalog record
| CREATOR | Vasiliki Zoi, Vasiliki Galani, Chrissa Sioka, Georgios A Alexiou, Athanassios P Kyritsis, Gabriella D’Orazi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |